In vitro antimycotic sensitivity of the genus candida yeast and lactobacillus rhamnosus probiotic strain
- Authors: Spasibova E.V.1,2, Savicheva A.M.1,2
-
Affiliations:
- The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott
- aint Petersburg State Pediatric Medical University
- Issue: Vol 68, No 5 (2019)
- Pages: 83-89
- Section: Original study articles
- URL: https://journals.rcsi.science/jowd/article/view/18733
- DOI: https://doi.org/10.17816/JOWD68583-89
- ID: 18733
Cite item
Full Text
Abstract
Hypothesis/aims of study. Vulvovaginal candidiasis (VVC) is one of the most common inflammatory diseases of the vagina. Herewith, a synergistic effect of lactobacilli and antifungal drugs in VVC treatment is suggested. In this regard, it seems relevant to study the effect of antimycotics used to treat VVC on the enhanced L. casei rhamnosus 35 (LCR35) probiotic strain. This study was aimed to determine the sensitivity to antimycotic drugs of the probiotic LCR35 strain included in the Lactoginal® vaginal capsules, as well as the sensibility of the genus Candida yeast under separate and joint cultivation with lactobacilli.
Study design, materials and methods. LCR35 was cultured on a MRS agar. Identification of bacteria grown on the medium, as well as clinical isolates of C. albicans and C. parapsilosis, isolated from the vagina, was performed by MALDI-TOF mass spectrometry. The sensitivity of yeast was determined on a modified Müller-Hinton agar with 40% glucose and methylene blue. Discs with fluconazole, voriconazole, itraconazole, ketoconazole, clotrimazole, and nystatin were used. Interpretation of growth inhibition zones was carried out according to EUCAST-2018 or according to the recommendations of the disc manufacturer.
Results. The probiotic LCR35 strain is resistant to antimycotics that are effective against C. albicans and C. parapsilosis. When determining the sensibility of C. albicans and C. parapsilosis to antimycotics in separate and joint cultivation with LCR35, no differences were found in the degree of yeast-like fungi growth suppression.
Conclusion. The probiotic LCR35 strain, which is part of the Lactoginal® vaginal capsules, is resistant to antimycotic drugs and does not affect the sensitivity of the tested yeast-like fungi to antimycotics.
Full Text
##article.viewOnOriginalSite##About the authors
Elena V. Spasibova
The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott; aint Petersburg State Pediatric Medical University
Author for correspondence.
Email: elena.rybina@gmail.com
MD. The Laboratory of Microbiology; Assistant. The Department of Clinical Laboratory Diagnostics. The Faculty of Postgraduate and Additional Professional Education
Russian Federation, Saint PetersburgAlevtina M. Savicheva
The Research Institute of Obstetrics, Gynecology, and Reproductology named after D.O. Ott; aint Petersburg State Pediatric Medical University
Email: savitcheva@mail.ru
MD, PhD, DSci (Medicine), Professor, Honoured Scholar of the Russian Federation, the Head of the Laboratory of Microbiology; the Head of the Department of Clinical Laboratory Diagnostics. The Faculty of Postgraduate and Additional Professional Education
Russian Federation, Saint PetersburgReferences
- Overman BA. The vagina as an ecologic system. Current understanding and clinical applications. J Nurse Midwifery. 1993;38(3):146-151. https://doi.org/10.1016/0091-2182(93)90038-i.
- Eckert L, Hawes SE, Stevens CE, et al. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998;92(5):757-765. https://doi.org/10.1016/S0029-7844(98)00264-6.
- Ross RA, Lee ML, Onderdonk AB. Effect of Candida albicans infection and clotrimazole treatment on vaginal microflora in vitro. Obstet Gynecol. 1995;86(6):925-930. https://doi.org/10.1016/0029-7844(95)00318-l.
- Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician. 2000;61(11):3306-3312, 3317.
- Будиловская О.В., Шипицына Е.В., Герасимова Е.Н., и др. Видовое разнообразие вагинальных лактобацилл в норме и при дисбиотических состояниях // Журнал акушерства и женских болезней. – 2017. – Т. 66. – № 2. – С. 24–32. [Budilovskaya OV, Shipitsyna EV, Gerasimova EN, et al. Species diversity of vaginal lactobacilli in norm and in dysbiotic states. Journal of Obstetrics and Women’s Diseases. 2017;66(2):24-32. (In Russ.)]. https://doi.org/10.17816/JOWD66224-32.
- Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA. 1996;275(11):870-876. https://doi.org/10.1001/jama.275. 11.870.
- Башмакова Н.В., Волкова Н.Ю., Гнатко Е.П., и др. Пробиотик для профилактики рецидивов вульвовагинального кандидоза (результаты международного многоцентрового открытого исследования РЕВОЛАКТ) // Акушерство и гинекология. – 2017. – № 6. – С. 136–142. [Bashmakova NV, Volkova NY, Gnatko EP, et al. Probiotics for prophylaxis of vulvovaginal candidiasis relapses: Results of the international multicenter open-label REVOLACT study. Akush Ginekol (Mosk). 2017;(6):136-142. (In Russ.)]. https://doi.org/10.18565/aig.2017.6.136-42.
- Манухин И.Б., Абашова Е.И., Базина М.И., и др. Лактобактерии LCR35 для профилактики рецидивов вульвовагинального кандидоза (результаты многоцентрового открытого неинтервенционного исследования) // Акушерство и гинекология. – 2018. – № 12. – С. 132–140. [Manukhin IB, Abashova EI, Bazina MI, et al. Lactobacteria LCR35 for prevention of relapse of vulvovaginal candidiasis: results of the multicenter open noninterventional study. Akush Ginekol (Mosk). 2018;(12):132-40. (In Russ.)]. https://doi.org/10.18565/aig.2018.12.132-140.
- Verdenelli MC, Coman MM, Cecchini C, et al. Evaluation of antipathogenic activity and adherence properties of human Lactobacillus strains for vaginal formulations. J Appl Microbiol. 2014;116(5):1297-1307. https://doi.org/10.1111/jam.12459.
- Савичева А.М., Рыбина Е.В. Исследование in vitro роста, размножения, антибиотикорезистентности, конкурентных взаимоотношений штамма Lactobacillus casei rhamnosus // Акушерство и гинекология. – 2014. – № 7. – С. 79–83. [Savicheva AM, Rybina EV. In vitro study of the growth, reproduction, antibiotic resistance, and competitive relationships of a Lactobacillus casei rhamnosus strain. Akush Ginekol (Mosk). 2014;(7):79-83. (In Russ.)]
- Ehrström S, Daroczy K, Rylander E, et al. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect. 2010;12(10):691-699. https://doi.org/10.1016/j.micinf.2010.04.010.
- Russo R, Superti F, Karadja E, et al. Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. 2019;62(4):328-335. https://doi.org/10.1111/myc.12883.
- De Gregorio PR, Silva JA, Marchesi A, et al. Anti-Candida activity of beneficial vaginal lactobacilli in in vitro assays and in a murine experimental model. FEMS Yeast Res. 2019;19(2). https://doi.org/10.1093/femsyr/foz008.
- Rossoni RD, de Barros PP, de Alvarenga JA, et al. Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis. Biofouling. 2018;34(2):212-225. https://doi.org/10.1080/08927014.2018.1425402.
- Allonsius CN, van den Broek MFL, De Boeck I, et al. Interplay between Lactobacillus rhamnosus GG and Candida and the involvement of exopolysaccharides. Microb Biotechnol. 2017;10(6):1753-1763. https://doi.org/10.1111/1751-7915.12799.
Supplementary files
